JP4847439B2 - Ln2O3コアを伴い生物学的リガンドを担持するハイブリッドナノ粒子及びその調製方法 - Google Patents
Ln2O3コアを伴い生物学的リガンドを担持するハイブリッドナノ粒子及びその調製方法 Download PDFInfo
- Publication number
- JP4847439B2 JP4847439B2 JP2007501308A JP2007501308A JP4847439B2 JP 4847439 B2 JP4847439 B2 JP 4847439B2 JP 2007501308 A JP2007501308 A JP 2007501308A JP 2007501308 A JP2007501308 A JP 2007501308A JP 4847439 B2 JP4847439 B2 JP 4847439B2
- Authority
- JP
- Japan
- Prior art keywords
- nanospheres
- nanoparticles
- coating
- molecules
- rare earth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims description 71
- 239000003446 ligand Substances 0.000 title claims description 30
- 238000000034 method Methods 0.000 title claims description 26
- 239000002077 nanosphere Substances 0.000 claims description 75
- -1 rare earth ions Chemical class 0.000 claims description 67
- 229920001296 polysiloxane Polymers 0.000 claims description 52
- 238000000576 coating method Methods 0.000 claims description 45
- 239000011248 coating agent Substances 0.000 claims description 42
- 239000002245 particle Substances 0.000 claims description 40
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 29
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 22
- 150000002602 lanthanoids Chemical class 0.000 claims description 19
- 150000002910 rare earth metals Chemical class 0.000 claims description 19
- 150000001768 cations Chemical class 0.000 claims description 18
- 229910052768 actinide Inorganic materials 0.000 claims description 16
- 150000001255 actinides Chemical class 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 16
- 239000002184 metal Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 229910052771 Terbium Inorganic materials 0.000 claims description 14
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 229910052693 Europium Inorganic materials 0.000 claims description 8
- 229910052779 Neodymium Inorganic materials 0.000 claims description 8
- 229910021645 metal ion Inorganic materials 0.000 claims description 8
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000005291 magnetic effect Effects 0.000 claims description 6
- 229910052691 Erbium Inorganic materials 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 229910052781 Neptunium Inorganic materials 0.000 claims description 4
- 229910052770 Uranium Inorganic materials 0.000 claims description 4
- 150000001412 amines Chemical group 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229910052774 Proactinium Inorganic materials 0.000 claims description 3
- 229910052776 Thorium Inorganic materials 0.000 claims description 3
- 229910052767 actinium Inorganic materials 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003169 water-soluble polymer Polymers 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 230000000536 complexating effect Effects 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 52
- 239000010410 layer Substances 0.000 description 46
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 39
- 239000000084 colloidal system Substances 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000004020 luminiscence type Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000003980 solgel method Methods 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000000975 dye Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000002372 labelling Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229920005862 polyol Polymers 0.000 description 7
- 150000003077 polyols Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229910052688 Gadolinium Inorganic materials 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 6
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000004054 semiconductor nanocrystal Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 4
- 229910052775 Thulium Inorganic materials 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002159 nanocrystal Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000002019 doping agent Substances 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- GFISHBQNVWAVFU-UHFFFAOYSA-K terbium(iii) chloride Chemical compound Cl[Tb](Cl)Cl GFISHBQNVWAVFU-UHFFFAOYSA-K 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DCQBZYNUSLHVJC-UHFFFAOYSA-N 3-triethoxysilylpropane-1-thiol Chemical compound CCO[Si](OCC)(OCC)CCCS DCQBZYNUSLHVJC-UHFFFAOYSA-N 0.000 description 2
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 229910052778 Plutonium Inorganic materials 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229910002005 actinide nitrate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000006862 quantum yield reaction Methods 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JXUKBNICSRJFAP-UHFFFAOYSA-N triethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CCO[Si](OCC)(OCC)CCCOCC1CO1 JXUKBNICSRJFAP-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229910052695 Americium Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229910052685 Curium Inorganic materials 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 229910052764 Mendelevium Inorganic materials 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000724 energy-dispersive X-ray spectrum Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 1
- 229940075613 gadolinium oxide Drugs 0.000 description 1
- 238000000024 high-resolution transmission electron micrograph Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 229910000311 lanthanide oxide Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004917 polyol method Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- KUKDDTFBSTXDTC-UHFFFAOYSA-N uranium;hexanitrate Chemical compound [U].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O KUKDDTFBSTXDTC-UHFFFAOYSA-N 0.000 description 1
- 229910002007 uranyl nitrate Inorganic materials 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1848—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a silane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
- C01F17/224—Oxides or hydroxides of lanthanides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/50—Solid solutions
- C01P2002/52—Solid solutions containing elements as dopants
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Materials Engineering (AREA)
- Geology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Luminescent Compositions (AREA)
Description
−2〜9nmの範囲に含まれる平均直径を有し、少なくとも90重量%がLn2O3から成り、ここでLnが任意には希土類又はアクチニドでドープされた希土類又は希土類混合物、又は希土類とアクチニドの混合物であり、ここで金属イオンの少なくとも50%が希土類イオンである、ナノスフェア;
−0.5〜10nmの範囲、好ましくは2nm超で10nm以下の範囲に含まれる平均厚みを有する、機能化されたポリシロキサンから主として成る、ナノスフェアのまわりのコーティング;及び
−ポリシロキサンコーティングに共有結合させることによりグラフト化された少なくとも1つの生物学的リガンド、
を含有するハイブリッドナノ粒子にある。
a)2〜9nmの範囲に含まれる平均直径を有し、少なくとも90重量%がLn2O3から成り、ここでLnが任意には希土類又はアクチニドでドープされた希土類又は希土類混合物、又は金属イオンの少なくとも50%が希土類イオンである希土類とアクチニドの混合物であるナノスフェアのコロイド懸濁液を調製する段階;
b)0.5〜10nmの範囲、好ましくは2nm超で10nm以下の範囲に含まれる平均厚みを有する、少なくとも1つの反応基で機能化されたポリシロキサンから主としてなる、粒子の表面上のコーティングを形成するのに必要な量のオルガノアルコキシシランと架橋剤の混合物をコロイド懸濁液に添加する段階;
c)コーティング表面上に存在する反応基とカップリングさせることにより、コーティングに対し少なくとも1つの生物学的リガンドを化学的にグラフト化する段階;
d)任意には、得られたハイブリッドナノ粒子を分離し乾燥させる段階、
を含んで成る、任意にはコロイド懸濁液の形をしている上述の通りのハイブリッドナノ粒子を調製する方法にある。
Tb3+で5%ドープされたGd2O3コロイドを、20ml体積のジエチレングリコールに50g.l-1量の塩化ガドリニウム及び塩化テルビウムの塩を溶解させることにより調製する。HRTEMで確認されレーザー粒子サイズ測定により測定された最終粒度は3.5nmである。コロイドを24時間、ジエチレングリコール中で加熱(40℃)及び撹拌下で透析する。独自のジエチレングリコールの体積と透析すべきコロイドの体積の比は20である。
t=0時間 APTS合計質量の16%に対応するm1の添加。
t=0.33時間 合計水体積の10%を添加することによるAPTSの加水分解。
t=1.33時間 残りのAPTS塊及び全TEOSに対応するm2の添加。
t=2.33時間 90%体積の残りの水の添加。
t=50.33時間 合成終了。
例1と同じ条件下でTb3+で5%ドープされたGd2O3のコロイドを調製する。
3.5nmのサイズに対応する、Tb3+で5%ドープされたGd2O3のコロイドを、例1と同じ条件下で調製する。以前に得たコロイドに対し適切な量の塩化ガドリニウム及び塩化テルビウム物の塩を添加することによって、同じ組成をもつサイズ5.7nmの粒子を得た。
5.7nmのサイズに対応する、Tb3+で5%ドープされたGd2O3のコロイドを、例3と同じ条件下で調製する。以前に得たコロイドに対し適切な量の塩化ガドリニウム及び塩化テルビウム物の塩を添加することによって、同じ組成をもつサイズ8nmの粒子を得た。
例1と同じ条件下でTb3+で5%ドープされたGd2O3のコロイドを調製する。
例1と同じ条件下でTb3+で5%ドープされたGd2O3のコロイドを調製する。
−COOH官能基で終る100μMd(T)22のオリゴヌクレオチド溶液を0.2MのEDC及び0.2MのNHS水溶液に添加する。1時間の撹拌後、(例1に従って調製され透析によって精製された)機能化されたポリシロキサンの層でコーティングされた酸化ガドリニウムのナノ粒子の水溶液500μlと緩衝液炭酸塩溶液100μl(0.1M;pH11)を、オリゴヌクレオチドストランドを含有する溶液に添加する。2時間の撹拌後、溶液はゲル化する。膜を通してろ過した後、ゲルを200μlのMilli−Q水に再分散させる。
ウラニウムで1%ドープされたGd2O3のコロイドを、20ml体積のジエチレングリコールに50g.l-1量の塩化ガドリニウム及び硝酸ウランの塩を溶解させることにより調製する。HRTEMで確認されレーザー粒子サイズ測定により測定された最終ナノスフェアサイズは3.5nmである。コロイドを24時間、ジエチレングリコール中で加熱(40℃)及び撹拌下で透析する。独自のジエチレングリコールの体積と透析すべきコロイドの体積の比は20である。
t=0時間 APTS合計質量の16%に対応するm1の添加。
t=0.33時間 合計水体積の10%を添加することによるAPTSの加水分解。
t=1.33時間 残りのAPTS塊及び全TEOSに対応するm2の添加。
t=2.33時間 残りの90%体積の水の添加。
t=50.33時間 合成終了。
モル単位でTb3+により5%及びEu3+により5%ドープされたGd2O3のコロイドを、50ml体積のジエチレングリコール(2.260gのGdCl3,6H2O、0.1273gのEuCl3,6H2O及び0.1250gのTbCl3,6H2O)に50g・l-1量の塩化ガドリニウム、テルビウム及びユーロビウムの塩を溶解させることによって調製する。70℃で2NのNaOHの水溶液3mlを添加し、1時間140℃まで、次に4時間180℃で加熱した後、HRTEMにより確認されレーザー粒度測定で測定した最終粒度は3.5nmである。ジエチレングリコール中で加熱(40℃)及び撹拌下でコロイドを24時間透析させる。独自のジエチレングリコールの体積と透析すべきコロイドの体積の比は20である。
−Ln2O3ナノスフェアをコーティングするポリシロキサン層上にグラフト化された有機染料分子の蛍光性、
−同一のナノスフェア内部でそのタイプが変動しうる、ナノスフェア内に取込まれたドーパントにより発出される電磁放射線(マルチドーピング)、
−特に常磁性であるガドリニウムセスキ酸化物を含有するナノスフェアのための磁気的測定、
によってその存在を明らかにすることのできる生物学的リガンドの標識及び検出のための、本発明のナノ粒子特にガドリニウムセスキ酸化物ナノスフェアの潜在的能力を確認するものである。
Claims (28)
- 2〜9nmの範囲に含まれる平均直径を有し、少なくとも90重量%がLn2O3から成り、ここでLnが、ドープされていないかもしくは希土類又はアクチニドでドープされた希土類又は希土類混合物、又は希土類とアクチニドの混合物であり、ここで金属イオンの少なくとも50%が希土類イオンである、ナノスフェア;
0.5〜10nmの範囲に含まれる平均厚みを有する、機能化されたポリシロキサンから主として成る、ナノスフェアのまわりのコーティング;及び
ポリシロキサンコーティングに共有結合させることによりグラフト化された少なくとも1つの生物学的リガンド、
を含有するハイブリッドナノ粒子。 - コーティング中、ケイ素原子の5〜75%が酸素架橋により4つのその他のケイ素原子に結合させられていることを特徴とする、請求項1に記載のナノ粒子。
- 10〜100000個の発光性有機分子が共有結合によりコーティングにグラフト化されていることを特徴とする、請求項1又は2に記載のナノ粒子。
- 前記発光性有機分子がローダミン又はフルオレセインの誘導体の中から選択されることを特徴とする、請求項3に記載のナノ粒子。
- ナノスフェアが、少なくとも80重量%について、ドープされていないかもしくはドープされた希土類セスキ酸化物から成ることを特徴とする、請求項1〜4のいずれか1項に記載のナノ粒子。
- ナノスフェアが、少なくとも80重量%について、Gd2O3から成ることを特徴とする、請求項5に記載のナノ粒子。
- ナノスフェアが、少なくとも80重量%について、Y 2O3から成ることを特徴とする、請求項5に記載のナノ粒子。
- ナノスフェアが、金属カチオンの0.1〜25%を占めるEu、Tb、Er、Nd、Yb、Tmタイプのランタニドでドープされていることを特徴とする、請求項1〜7のいずれか1項に記載のナノ粒子。
- ナノスフェアがNd又はYbタイプのランタニドでドープされていることを特徴とする、請求項8に記載のナノ粒子。
- ナノスフェアがErタイプのランタニドでドープされていることを特徴とする、請求項8に記載のナノ粒子。
- ナノスフェアが金属カチオンの0.1〜25%を占める少なくとも2つの異なるランタニドでドープされており、これらのランタニドの少なくとも1つはEu及びTbの中から選択されることを特徴とする、請求項1〜7のいずれか1項に記載のナノ粒子。
- ナノスフェアの金属カチオンの10%超が、Gd、Ndの中から選択された磁気的挙動を有するランタニドカチオンであることを特徴とする、請求項1〜5のいずれか1項に記載のナノ粒子。
- ナノスフェアの金属カチオンの50%超が、Gd、Ndの中から選択された磁気的挙動を有するランタニドカチオンであることを特徴とする、請求項1〜5のいずれか1項に記載のナノ粒子。
- ナノスフェアの金属カチオンの0.01%〜50%が、Ac、Th、Pa、Np、U、Np、Puの中から選択されたウラニドカチオンであることを特徴とする、請求項1〜5のいずれか1項に記載のナノ粒子。
- 広範な中性子捕捉能力を有するナノスフェアの金属カチオンの少なくとも1%が、同位体157Gd及び235Uの中から選択されることを特徴とする、請求項1〜14のいずれか1項に記載のナノ粒子。
- 生物学的リガンドの1〜1000個の分子が、共有結合によりコーティング上にグラフト化されることを特徴とする、請求項1〜15のいずれか1項に記載のナノ粒子。
- ナノ粒子の10重量%未満が、コーティング上にグラフト化された生物学的リガンドの2個超の分子を含有することを特徴とする、請求項1〜15のいずれか1項に記載のナノ粒子。
- グラフト化された単数又は複数の生物学的リガンドが、ヌクレオチド、糖、ビタミン、ホルモン、ビオチン又はストレプトアビジンから誘導されることを特徴とする、請求項1〜17のいずれか1項に記載のナノ粒子。
- 生物学的リガンド以外の発光性分子又は錯化分子がコーティング上にグラフト化されることを特徴とする、請求項1〜18のいずれか1項に記載のナノ粒子。
- 有機リン酸エステル、第4級アミンタイプの極性又は荷電分子がコーティング上にグラフト化されていることを特徴とする、請求項1〜19のいずれか1項に記載のナノ粒子。
- 5000g/モル未満の分子量を有する水溶性重合体の分子がコーティング上にグラフト化されることを特徴とする、請求項1〜19のいずれか1項に記載のナノ粒子。
- 請求項1〜21のいずれか1項に記載のハイブリッドナノ粒子のコロイド懸濁液。
- a)2〜9nmの範囲に含まれる平均直径を有し、少なくとも90重量%がLn2O3から成り、ここでLnが、ドープされていないかもしくは希土類又はアクチニドでドープされた希土類又は希土類混合物、又は金属イオンの少なくとも50%が希土類イオンである希土類とアクチニドの混合物であるナノスフェアのコロイド懸濁液を調製する段階;
b)0.5〜10nmの範囲に含まれる平均厚みを有する、少なくとも1つの反応基で機能化されたポリシロキサンから主としてなる、粒子の表面上のナノスフェアのまわりのコーティングを形成するのに必要な量のオルガノアルコキシシランと架橋剤の混合物をコロイド懸濁液に添加する段階;
c)コーティング表面上に存在する反応基とカップリングさせることにより、コーティングに対し少なくとも1つの生物学的リガンドを化学的にグラフト化する段階;
を含んで成ることを特徴とする、請求項1〜21のいずれか1項に記載のハイブリッドナノ粒子を調製する方法。 - 段階a)において、溶媒1リットルあたり100mgと100gの間のナノスフェアを含有するコロイド懸濁液が、極性溶媒の中に希土類及び/又はアクチニドの前駆物質を溶解させること及び、少なくとも所望のセスキ酸化物を形成するのに必要な量の水の存在下で130〜250℃の間の温度まで加熱することによって調製されることを特徴とする、請求項23に記載の調製方法。
- 希土類又はアクチニドの前駆体が、塩化物、酢酸塩又は硝酸塩タイプであることを特徴とする、請求項24に記載の方法。
- 段階b)で、架橋剤としてオルトケイ酸テトラエチル(TEOS)を使用することを特徴とする、請求項23〜25のいずれか1項に記載の方法。
- 使用されるオルガノアルコキシシランの分子の一部が、発光性分子に共有結合されることを特徴とする、請求項23〜26のいずれか1項に記載の方法。
- 段階c)の前には、コーティング表面上に存在する反応基とカップリングさせることによる、発光性分子及び/又は錯化分子及び/又は極性又は荷電分子及び/又は水溶性重合体分子のグラフト化段階が先行していることを特徴とする、請求項23〜27のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0402115 | 2004-03-02 | ||
FR0402115A FR2867180B1 (fr) | 2004-03-02 | 2004-03-02 | Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation |
PCT/FR2005/000491 WO2005088314A1 (fr) | 2004-03-02 | 2005-03-02 | Nanoparticules hybrides comprenant un coeur de ln2o3 porteuses de ligands biologiques et leur procede de preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007526471A JP2007526471A (ja) | 2007-09-13 |
JP4847439B2 true JP4847439B2 (ja) | 2011-12-28 |
Family
ID=34854964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007501308A Active JP4847439B2 (ja) | 2004-03-02 | 2005-03-02 | Ln2O3コアを伴い生物学的リガンドを担持するハイブリッドナノ粒子及びその調製方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8357545B2 (ja) |
EP (1) | EP1723431B1 (ja) |
JP (1) | JP4847439B2 (ja) |
CN (1) | CN1973204A (ja) |
CA (1) | CA2558033C (ja) |
FR (1) | FR2867180B1 (ja) |
WO (1) | WO2005088314A1 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2867180B1 (fr) | 2004-03-02 | 2006-06-16 | Univ Claude Bernard Lyon | Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation |
AU2008212556A1 (en) * | 2007-02-07 | 2008-08-14 | Spago Imaging Ab | Visualization of biological material by the use of coated contrast agents |
FR2922106B1 (fr) * | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
FR2930890B1 (fr) * | 2008-05-06 | 2010-12-10 | Univ Claude Bernard Lyon | Nouveaux agents de radiotherapie ciblee ou de curietherapie a base d'oxydes ou d'oxo-hydroxydes de terre rare |
EP2404977B1 (en) * | 2009-03-06 | 2016-05-11 | Ocean's King Lighting Science&Technology Co., Ltd. | Preparation of luminescent oxide materials activated by trivalent thulium |
CN101885905B (zh) * | 2009-05-12 | 2013-08-21 | 无锡纳奥新材料科技有限公司 | 聚合物/无机纳米粒子复合纳米颗粒及其制备和用途 |
FR2954796B1 (fr) | 2009-12-24 | 2016-07-01 | Total Sa | Utilisation de nanoparticules pour le marquage d'eaux d'injection de champs petroliers |
FR2959502B1 (fr) | 2010-04-30 | 2012-09-07 | Nanoh | Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie |
KR101221375B1 (ko) | 2010-09-14 | 2013-01-11 | 전남대학교산학협력단 | 고휘도 청색 발광 나노콜로이드 및 이의 제조방법 |
FR2976825B1 (fr) | 2011-06-22 | 2014-02-21 | Total Sa | Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers |
FR2976967B1 (fr) | 2011-06-22 | 2015-05-01 | Total Sa | Fluides traceurs a effet memoire pour l'etude d'un gisement petrolier |
FR2981849B1 (fr) * | 2011-10-28 | 2014-01-03 | Univ Claude Bernard Lyon | Nanoparticules fonctionnalisees pour le ciblage des proteoglycanes et leurs applications |
FR2989280B1 (fr) | 2012-04-13 | 2017-02-24 | Univ Claude Bernard Lyon | Nanoparticules ultrafines comme agent de contraste multimodal |
WO2014146215A1 (en) * | 2013-03-19 | 2014-09-25 | Land And Long International Trading Co. Limited | Method and apparatus for time-resolved fluorescence immunoassay testing |
FR3008797A1 (fr) * | 2013-07-19 | 2015-01-23 | Total Sa | Procede d'identification de composes d'un melange organique et kit pour la mise en oeuvre de ce procede |
US9409148B2 (en) | 2013-08-08 | 2016-08-09 | Uchicago Argonne, Llc | Compositions and methods for direct capture of organic materials from process streams |
KR101468816B1 (ko) * | 2013-09-03 | 2014-12-04 | 한국원자력연구원 | 졸-겔 반응에 의한 방사성 동위원소 하이브리드 나노복합체 입자의 제조 방법 및 그 방법으로 제조된 방사성 동위원소 하이브리드 나노복합체 입자 |
CN104164233A (zh) * | 2014-05-23 | 2014-11-26 | 贵州大学 | 核壳结构稀土纳米颗粒的制备方法 |
EP3551231A4 (en) | 2016-12-08 | 2020-08-12 | The Brigham and Women's Hospital, Inc. | BISMUTH GADOLINIUM NANOPARTICLE |
EP3424533A1 (en) | 2017-07-05 | 2019-01-09 | Nh Theraguix | Methods for treating tumors |
ES2859775T3 (es) * | 2018-07-05 | 2021-10-04 | Univ Strasbourg | Nanopartículas de lantánido luminiscentes ultrabrillantes que comprenden terbio, con una mayor vida útil de estado excitado |
AU2019458882A1 (en) | 2019-07-29 | 2022-02-17 | Centre Hospitalier Universitaire De Grenoble | Methods for treating tumors |
FR3099883A1 (fr) | 2019-08-14 | 2021-02-19 | Nh Theraguix | Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence |
EP3795178A1 (en) | 2019-09-19 | 2021-03-24 | Nh Theraguix | Methods for triggering m1 macrophage polarization |
AU2021270780A1 (en) | 2020-05-15 | 2022-11-24 | Centre Georges-François Leclerc | Methods for image-guided radiotherapy |
FR3116197A1 (fr) | 2020-11-19 | 2022-05-20 | Nh Theraguix | Procédé de traitement de tumeurs par captation du cuivre et/ou du fer |
FR3116216B1 (fr) | 2020-11-19 | 2023-10-27 | Nh Theraguix | Procédé de préparation de nanoparticules |
FR3124799A1 (fr) * | 2021-06-30 | 2023-01-06 | Aledia | Nanoparticule émettrice de lumière et protégée, son procédé de fabrication et son application pour les convertisseurs de rayonnement de dispositif optoélectronique |
WO2024013272A1 (en) | 2022-07-13 | 2024-01-18 | Universite De Montpellier | Combined therapy with nanoparticles and radiopharmaceuticals |
WO2024083937A2 (en) | 2022-10-18 | 2024-04-25 | Nh Theraguix | Methods for imaging using spcct |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000034409A (ja) * | 1998-05-29 | 2000-02-02 | Bayer Ag | 鉱物建材の水性製剤処理 |
JP2001324507A (ja) * | 2000-05-18 | 2001-11-22 | Nano Career Kk | イムノナノスフェアーを含有する免疫測定用組成物 |
JP2003034526A (ja) * | 2001-07-18 | 2003-02-07 | Kinya Adachi | 希土類酸化物ナノ粒子の製造方法 |
US20030180780A1 (en) * | 2002-03-19 | 2003-09-25 | Jun Feng | Stabilized inorganic particles |
JP2003532898A (ja) * | 2000-05-05 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 生体標識としてのドープ処理されたナノ粒子 |
WO2005054858A1 (fr) * | 2003-11-28 | 2005-06-16 | Universite Claude Bernard Lyon I | Nouvelles sondes hybrides a luminescence exaltee |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4283382A (en) | 1977-12-28 | 1981-08-11 | Eastman Kodak Company | Fluorescent labels comprising rare earth chelates |
US4259313A (en) | 1978-10-18 | 1981-03-31 | Eastman Kodak Company | Fluorescent labels |
US4921589A (en) * | 1988-12-20 | 1990-05-01 | Allied-Signal Inc. | Polysiloxane bound photosensitizer for producing singlet oxygen |
DE4117782C2 (de) * | 1991-05-28 | 1997-07-17 | Diagnostikforschung Inst | Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel |
US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
US6099964A (en) * | 1997-02-06 | 2000-08-08 | Wacker-Chemie Gmbh | Metal deposits on mesoscopic organopolysiloxane particles |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
WO2000006244A2 (en) | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
EP1116036B1 (en) | 1998-09-18 | 2004-08-11 | Massachusetts Institute Of Technology | Water-soluble fluorescent semiconductor nanocrystals |
DE69938353T2 (de) | 1998-09-24 | 2009-03-05 | Indiana University Research and Technology Corp., Indianapolis | Wasserlösliche lumineszente quantum-dots sowie deren biokonjugate |
US20020006632A1 (en) * | 2000-02-24 | 2002-01-17 | Gopalakrishnakone Ponnampalam | Biosensor |
GB0027516D0 (en) * | 2000-11-10 | 2000-12-27 | Amersham Pharm Biotech Uk Ltd | Support and method for cell based assays |
US6783699B2 (en) * | 2002-10-17 | 2004-08-31 | Medgene, Inc. | Europium-containing fluorescent nanoparticles and methods of manufacture thereof |
FR2867180B1 (fr) | 2004-03-02 | 2006-06-16 | Univ Claude Bernard Lyon | Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation |
FR2869803B1 (fr) | 2004-05-10 | 2006-07-28 | Nanobiotix Sarl | Particules activables, preparation et utilisations |
WO2006012201A1 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Nanoparticles for imaging atherosclerotic plaque |
FR2877571B1 (fr) | 2004-11-05 | 2007-04-13 | Nanobiotix Sarl | Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations |
FR2898519B1 (fr) * | 2006-03-20 | 2009-01-09 | Commissariat Energie Atomique | Nanoparticules notamment a structure coeur coquilles, enrobees |
-
2004
- 2004-03-02 FR FR0402115A patent/FR2867180B1/fr not_active Expired - Fee Related
-
2005
- 2005-03-02 WO PCT/FR2005/000491 patent/WO2005088314A1/fr active Application Filing
- 2005-03-02 CA CA2558033A patent/CA2558033C/fr active Active
- 2005-03-02 EP EP05733006A patent/EP1723431B1/fr active Active
- 2005-03-02 CN CNA2005800065984A patent/CN1973204A/zh active Pending
- 2005-03-02 US US10/591,465 patent/US8357545B2/en active Active
- 2005-03-02 JP JP2007501308A patent/JP4847439B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000034409A (ja) * | 1998-05-29 | 2000-02-02 | Bayer Ag | 鉱物建材の水性製剤処理 |
JP2003532898A (ja) * | 2000-05-05 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 生体標識としてのドープ処理されたナノ粒子 |
JP2001324507A (ja) * | 2000-05-18 | 2001-11-22 | Nano Career Kk | イムノナノスフェアーを含有する免疫測定用組成物 |
JP2003034526A (ja) * | 2001-07-18 | 2003-02-07 | Kinya Adachi | 希土類酸化物ナノ粒子の製造方法 |
US20030180780A1 (en) * | 2002-03-19 | 2003-09-25 | Jun Feng | Stabilized inorganic particles |
WO2005054858A1 (fr) * | 2003-11-28 | 2005-06-16 | Universite Claude Bernard Lyon I | Nouvelles sondes hybrides a luminescence exaltee |
Also Published As
Publication number | Publication date |
---|---|
FR2867180A1 (fr) | 2005-09-09 |
JP2007526471A (ja) | 2007-09-13 |
CN1973204A (zh) | 2007-05-30 |
EP1723431B1 (fr) | 2012-09-05 |
CA2558033A1 (fr) | 2005-09-22 |
CA2558033C (fr) | 2013-04-16 |
WO2005088314A1 (fr) | 2005-09-22 |
FR2867180B1 (fr) | 2006-06-16 |
EP1723431A1 (fr) | 2006-11-22 |
US8357545B2 (en) | 2013-01-22 |
US20070281324A1 (en) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4847439B2 (ja) | Ln2O3コアを伴い生物学的リガンドを担持するハイブリッドナノ粒子及びその調製方法 | |
Louis et al. | Nanosized hybrid particles with double luminescence for biological labeling | |
EP1473347B1 (en) | Core/shell nanoparticles suitable for (F) RET-assays | |
Soukka et al. | Photon upconversion in homogeneous fluorescence‐based bioanalytical assays | |
Bouzigues et al. | Biological applications of rare-earth based nanoparticles | |
US9675953B2 (en) | Encapsulated particles | |
Escribano et al. | Photonic and nanobiophotonic properties of luminescent lanthanide-doped hybrid organic–inorganic materials | |
Runowski et al. | Preparation of biocompatible, luminescent-plasmonic core/shell nanomaterials based on lanthanide and gold nanoparticles exhibiting SERS effects | |
Fritzen et al. | Opportunities for persistent luminescent nanoparticles in luminescence imaging of biological systems and photodynamic therapy | |
WO2008033804A2 (en) | Quantum dot barcode structures and uses thereof | |
Runowski et al. | Magnetic and luminescent hybrid nanomaterial based on Fe 3 O 4 nanocrystals and GdPO 4: Eu 3+ nanoneedles | |
Dosev et al. | Inorganic lanthanide nanophosphors in biotechnology | |
JP2007512522A (ja) | 強発光を有する新規のハイブリッド・プローブ | |
Markova et al. | Synthesis and properties of core–shell fluorescent hybrids with distinct morphologies based on carbon dots | |
Darbandi et al. | Silica coated, water dispersible and photoluminescent Y (V, P) O4: Eu3+, Bi3+ nanophosphors | |
Pinho et al. | Silica nanoparticles for bimodal MRI–optical imaging by grafting Gd3+ and Eu3+/Tb3+ complexes | |
Lee et al. | Highly luminescent and long-term anti-photobleaching Eu (TTA) 3 (TOP) 3 conjugated poly (St-co-DVB-co-NaSS-co-MAA) nanoparticles | |
Jiang et al. | Glucose oxidase-encapsulated liposomes for amplified autofluorescence-free immunoassay of a prostate-specific antigen with photoluminescence of CePO 4: Tb nanocrystals | |
Kong et al. | Avidin conjugation to up-conversion phosphor NaYF 4: Yb 3+, Er 3+ by the oxidation of the oligosaccharide chains | |
Ansari et al. | Surface Coating Effect on Structural, Optical and Photoluminescence Properties of Eu 3+ Doped Yttrium Fluoride Nanoparticles | |
CN109321245A (zh) | 一种稀土双掺杂功能纳米复合材料及其制备方法 | |
Truillet et al. | Energy transfer from pyridine molecules towards europium cations contained in sub 5-nm Eu2O3 nanoparticles: Can a particle be an efficient multiple donor-acceptor system? | |
Li et al. | Preparation, characterization, and fabrication of uniform coated Y2O2S: RE3+ up-converting phosphor particles for biological detection applications | |
Le et al. | Fluorescence Resonance Energy Transfer System Between ZnSe Nanoparticles Encapsulated by Silica and Gold Nanoparticles for Detection of Dopamine | |
Silvares | Desenvolvimento e Aplicação de Polioxometalatos Funcionalizados Como Marcadores Fluorescentes em Biossensores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080221 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100521 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100729 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110818 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110913 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111013 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4847439 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |